X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
everolimus (265) 265
index medicus (263) 263
humans (249) 249
oncology (241) 241
breast cancer (216) 216
female (198) 198
breast neoplasms - drug therapy (162) 162
breast neoplasms - pathology (113) 113
cancer (112) 112
endocrine therapy (99) 99
metastasis (94) 94
postmenopausal women (94) 94
everolimus plus exemestane (89) 89
care and treatment (88) 88
sirolimus - analogs & derivatives (87) 87
chemotherapy (85) 85
middle aged (81) 81
antineoplastic combined chemotherapy protocols - therapeutic use (80) 80
double-blind (80) 80
mammalian target (80) 80
aged (76) 76
tor serine-threonine kinases - antagonists & inhibitors (72) 72
mtor (68) 68
breast neoplasms - metabolism (67) 67
adult (64) 64
antineoplastic agents - therapeutic use (64) 64
pharmacology & pharmacy (56) 56
tamoxifen (56) 56
treatment outcome (55) 55
randomized phase-ii (51) 51
estrogen (50) 50
rapamycin (50) 50
receptors, estrogen - metabolism (50) 50
metastatic breast cancer (49) 49
medicine & public health (48) 48
renal-cell carcinoma (48) 48
research (48) 48
sirolimus - administration & dosage (48) 48
drug therapy (46) 46
neoplasm metastasis (44) 44
receptor, erbb-2 - metabolism (44) 44
therapy (44) 44
trial (44) 44
cancer therapies (43) 43
endocrine resistance (43) 43
analysis (42) 42
everolimus - administration & dosage (42) 42
sirolimus - adverse effects (42) 42
advanced breast cancer (41) 41
aged, 80 and over (41) 41
aromatase inhibitors (41) 41
disease-free survival (41) 41
exemestane (41) 41
fulvestrant (41) 41
sirolimus - therapeutic use (41) 41
androstadienes - administration & dosage (40) 40
hematology, oncology and palliative medicine (40) 40
mtor inhibitor (39) 39
mtor inhibitors (39) 39
review (39) 39
tumors (39) 39
clinical trials (37) 37
health aspects (37) 37
antineoplastic agents - adverse effects (36) 36
combination (36) 36
breast neoplasms - genetics (35) 35
patients (35) 35
progression-free survival (35) 35
resistance (35) 35
antineoplastic combined chemotherapy protocols - adverse effects (34) 34
development and progression (34) 34
animals (32) 32
estrogen-receptor (32) 32
letrozole (32) 32
everolimus - therapeutic use (31) 31
trastuzumab (31) 31
neoplasms. tumors. oncology. including cancer and carcinogens (29) 29
plus exemestane (29) 29
signal transduction - drug effects (29) 29
survival (29) 29
temsirolimus (29) 29
efficacy (28) 28
kinases (28) 28
mutation (28) 28
postmenopause (28) 28
tor protein (28) 28
angiogenesis inhibitors (27) 27
stomatitis (27) 27
tor serine-threonine kinases - metabolism (27) 27
antineoplastic agents, hormonal - therapeutic use (26) 26
male (26) 26
phase-iii trial (26) 26
protein kinase inhibitors - therapeutic use (26) 26
1st-line treatment (25) 25
everolimus - adverse effects (25) 25
drug resistance, neoplasm (24) 24
growth (24) 24
metastases (24) 24
receptors, progesterone - metabolism (24) 24
signal transduction (24) 24
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Advances in Therapy, ISSN 0741-238X, 10/2013, Volume 30, Issue 10, pp. 870 - 884
Journal Article
Cancer, ISSN 0008-543X, 05/2013, Volume 119, Issue 10, pp. 1908 - 1915
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 2/2014, Volume 143, Issue 3, pp. 459 - 467
Journal Article
Current Medical Research & Opinion, ISSN 0300-7995, 11/2013, Volume 29, Issue 11, pp. 1463 - 1473
Journal Article
The Oncologist, ISSN 1083-7159, 07/2019, Volume 24, Issue 7, pp. 893 - 900
Background The prognostic and predictive value of the two nonluminal (human epidermal growth factor receptor 2 [HER2]‐enriched and basal‐like) subtypes within... 
Intrinsic subtype | Advanced breast cancer | Exemestane | Everolimus | Mammalian target of rapamycin | ONCOLOGY | RANDOMIZED PHASE-II | CLINICAL-IMPLICATIONS | LETROZOLE | OUTCOMES
Journal Article
Journal Article
International Journal of Cancer, ISSN 0020-7136, 02/2019, Volume 144, Issue 4, pp. 877 - 885
Journal Article
BioMed Research International, ISSN 2314-6133, 2018, Volume 2018, pp. 3756981 - 8
Journal Article
Annals of Oncology, ISSN 0923-7534, 09/2016, Volume 27, Issue 9, pp. 1719 - 1725
Journal Article
Medical Oncology, ISSN 1357-0560, 4/2018, Volume 35, Issue 4, pp. 1 - 7
Metastatic breast cancer (MBC) is essentially incurable despite recent improvements in systemic therapies. We often encounter difficulties in choosing the most... 
Pathology | Biomarker | pS6 | Medicine & Public Health | Hematology | Oncology | Internal Medicine | Metastatic breast cancer | Ki67 | Everolimus | ACTIVATION | ENDOCRINE THERAPY | TRIAL | IMPACT | ONCOLOGY | PATHWAY | BOLERO-3 | PROTEIN S6 KINASE | Medical colleges | Care and treatment | Breast cancer | Metastasis | Labeling | Cancer therapies
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 7/2015, Volume 152, Issue 1, pp. 95 - 117
Journal Article